TG THERAPEUTICS, INC. (TGTX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 745.39M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 1.64B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $745.39M | (m) | (m) | $1.64B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $745.14M | (m) | (m) | $1.53B | (m) |
| 2025-12-31 | (m) | (m) | (m) | $245.65M | (m) | (m) | $1.06B | (m) |
| 2025-09-30 | (m) | (m) | (m) | $245.34M | (m) | (m) | $1.03B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $245.04M | (m) | (m) | $702.61M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $244.73M | (m) | (m) | $656.69M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $244.43M | (m) | (m) | $577.69M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $244.16M | (m) | (m) | $586.01M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $102.54M | (m) | (m) | $401.21M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $101.33M | (m) | (m) | $373.32M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $100.12M | (m) | (m) | $329.59M | (m) |
| 2023-09-30 | (m) | (m) | $0.00 | $98.91M | (m) | (m) | $331.07M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $97.70M | (m) | (m) | $220.85M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $96.50M | (m) | (m) | $197.36M | (m) |
| 2022-12-31 | (m) | (m) | $0.00 | $71.14M | (m) | (m) | $193.57M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $70.04M | (m) | (m) | $217.89M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $68.95M | (m) | (m) | $251.67M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $67.25M | (m) | (m) | $303.03M | (m) |
| 2021-12-31 | (m) | (m) | $975.00K | $66.79M | (m) | (m) | $379.63M | (m) |
| 2021-09-30 | (m) | (m) | $16.00M | (m) | (m) | (m) | $409.69M | (m) |
| 2021-06-30 | (m) | (m) | $23.16M | (m) | (m) | (m) | $481.40M | (m) |
| 2021-03-31 | (m) | (m) | $30.13M | (m) | (m) | (m) | $548.70M | (m) |
| 2020-12-31 | (m) | (m) | $22.18M | $7.72M | (m) | (m) | $625.64M | (m) |
| 2020-09-30 | (m) | (m) | $14.59M | $15.07M | (m) | (m) | $273.86M | (m) |
| 2020-06-30 | (m) | (m) | $7.20M | $22.23M | (m) | (m) | $294.62M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $29.20M | (m) | (m) | $101.85M | (m) |
| 2019-12-31 | (m) | (m) | $0.00 | $28.97M | (m) | (m) | $163.01M | (m) |
| 2019-09-30 | (m) | (m) | $0.00 | $28.74M | (m) | (m) | $93.33M | (m) |
| 2019-06-30 | (m) | (m) | $0.00 | $28.51M | (m) | (m) | $106.58M | (m) |
| 2019-03-31 | (m) | (m) | $0.00 | $28.29M | (m) | (m) | $117.54M | (m) |
| 2018-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $83.62M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |